Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal imbalance. Its development stage products include PRAX-114, PRAX-944 and PRAX-562. PRAX-114 is an extrasynaptic-preferring gamma-aminobutyric acid-A (GABAA) receptor positive allosteric modulator (PAM) for the treatment of patients suffering from major depressive disorder (MDD) and perimenopausal depression (PMD). PRAX-944 is a differentiated selective small molecule inhibitor of T-type calcium channel, for the treatment of essential tremor (ET). PRAX-562 is the selective, persistent sodium current blocker in development for the treatment of a range of CNS disorders.